 Co-Diagnostics Inc NASDAQ:CODX ended its second quarter of 2022 with a cash balance of US96 million to help it progress development of its Co-Dx PCR Home testing platform for infectious diseases. During the three-month period to end June 30, 2022, the company completed the principal design for a monkeypox virus test and shipped testing reagents to its international distributor. 